364 reports of this reaction
2.0% of all UMECLIDINIUM reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for UMECLIDINIUM, manufactured by GlaxoSmithKline LLC. There are 364 FDA adverse event reports linking UMECLIDINIUM to FATIGUE. This represents approximately 2.0% of all 18,218 adverse event reports for this drug.
Patients taking UMECLIDINIUM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for UMECLIDINIUM, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for UMECLIDINIUM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 364 FDA reports for UMECLIDINIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.0% of all adverse event reports for UMECLIDINIUM, making it a notable side effect.
If you experience fatigue while taking UMECLIDINIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.